Perindopril

Combination of perindopril indapamide versus enalapril. This was 2.5%, 24 with an assumed limit of determined by using an noninferiority at the final visit being a clinically significant difference in AER 35% of the value in the enalapril group ; .25 The sample size was calculated to be 200 patients per group.26 AER and.
Perindopril is an angiotensin-converting-enzyme inhibitor ACEI ; . It is prodrug with a 27 hour half-life metabolite Perindoprilate ; . ACEI are associated with many respiratory side-effects [1]; the most frequently reported being dry cough with or without bronchial hyperreactivity [2]. Two case reports have suggested the possibility of the uncovering of an asthmatic tendency [3] and development of persistent late onset asthma following treatment with captopril. ACEI seems to be incriminated in the genesis and metabolism of bronchomotor mediators [4]. In a recent paper, 36 cases of ACEIinduced life-threatening angioedema were reported between 1984 and 1991 and, for patients with recurring episodes, hereditory factors were considered [5]. Pneumonitis is not a frequent side-effect: we report two cases of perindopril-associated pneumonitis with similar clinical features and different anatomical aspects on microscopic examination. Case 1 A 60 year old man was admitted to hospital in May 1991 with dyspnoea, fever and sweats. He had lost 6 kg in weight within 6 weeks. He was a smoker, with no professional exposure, and had been treated with captopril 50 mg for high blood pressure from 1989 to January 1991. Captopril had been discontinued and another ACEI, perindopril 4 mg, introduced. His treatment was completed with benfluorex, endotelon, diosmine since 1991. He had never had any respiratory symptoms. Physical examination revealed bilateral crackles with a right predominance. Chest radiographic film showed infiltrates in both upper lung fields. Computed tomography revealed peripheral lesions associating reticulonodular infiltrates with groundglass pattern, and alveolar infiltration on the middle right field without lymph node enlargment fig. 1 ; . Blood. Presentation of the final Conference Statement The three-day event closed with the circulation and reading of the State-of-the-Science Panel to the public at large, and at a press conference for medical and health reporters on the final day. The essence of the conclusions by the group charged with writing the Statement can best be summarized in this excerpt from the document: ". Most of these studies do not provide strong evidence for beneficial health-related effects of supplements singly, in pairs, or in combinations of three or more Finally, the present evidence is insufficient to recommend either for or against the use of MVMs by the American public to prevent chronic disease. The suggested effects to date merit further investigation to determine the impact of vitamin and mineral supplementation on chronic disease." Clearly, with the exception of the Linxian, China, experience, the central questions were being asked and answered for the North American ambience, with a generally well-nourished population with dietary micronutrients coming from enrichment and fortification. To the extent that chronic diseases are emerging in low-income societies, in which micronutrient deficiencies are common, an analogous question about MVM use and disease prevention would emerge. Lack of awareness of chronic disease risk in developing countries and the very nature of their economic deprivation, however, make the financing and conduct of well-designed prevention trials with MVM in malnourished population settings an unlikely eventuality.

Lin cells remained lower than in normal mice. Mice grafted with marrow cells from perindopril-treated mice also appeared to contain slightly more cells with a more primitive phenotype, Lin Sca c-kit 0.14% ; , than those grafted with bone marrow from irradiated mice P .07 ; . However, the frequency of the Lin Sca c-kit cells remained 2-fold lower in mice grafted with marrow cells from mice treated with perindopril than in those grafted with normal bone marrow 0.31.
Pregnancy: COVERSYL ARGININE PLUS 5mg 1.25mg should not be used during the first trimester of pregnancy. When a pregnancy is planned or confirmed the switch to an alternative treatment should be initiated as soon as possible. Controlled studies with ACE inhibitors have not been done in humans, but in a limited number of cases with first trimester exposure there do not appear to have been any malformations consistent with human fetotoxicity as described below. COVERSYL ARGININE PLUS 5mg 1.25mg is contraindicated during the second and third trimesters of pregnancy see section 4.3 ; . Prolonged ACE inhibitors exposure during the second and third trimesters is known to induce human fetotoxicity decreased renal function, oligohydramnios, retardation of skull ossification ; and neonatal toxicity renal failure, hypotension, hyperkalemia ; see section 5.3 ; . Prolonged exposure to thiazide during the third trimester of pregnancy can reduce maternal plasma volume as well as uteroplacental blood flow, which may cause a feto-placental ischemia and growth retardation. Moreover, rare cases of hypoglycemia and thrombocytopenia in neonates have been reported following exposure near term. Should exposure to COVERSYL ARGININE PLUS 5mg 1.25mg have occurred from the second trimester of pregnancy, an ultrasound check of renal function and the skull is recommended. Lactation : COVERSYL ARGININE PLUS 5mg 1.25mg is contraindicated during lactation. The excretion of perindopril into breast milk is unknown. Indapamide is excreted in human milk. Indapamide is closely related to thiazide diuretics which have been associated, during breast-feeding, with decrease or even suppression of milk lactation. Hypersensitivity to sulfonamide-derived drugs, hypokalaemia and nuclear icterus might occur. As, with both drugs, serious adverse reactions might occur in nursing infants, a decision should be made whether to discontinue nursing or to discontinue therapy taking account the importance of this therapy for the mother. 4.7 Effects on ability to drive and use machines Linked to perindopril, indapamide and COVERSYL ARGININE PLUS 5mg 1.25mg!

ACKNOWLEDGMENT The study was supported by a grant from Servier, Suresnes, France. The authors thank Patrice Ardouin and Annie Rouchs for taking care of the mice, Franoise Le Pesteur for her technical assistance, Christopher McNamara for improving the English of the manuscript and Ferdinand Le Noble for critical reading of the manuscript. Enantiomer S-11579 ; and perindopril Coversyl ; kindly provided by Servier Institute, telmisatan Micardis ; by Boehringer Ingelheim, France. RXP407 was given by J. Cotton, V. Dive, CEA de Saclay, France and A. Yiotakis, University of Athens, Greece and carvedilol.

Secondly, to investigate if intensive glucose control decreases the incidence and progression of diabetic retinal lesions compared to standard guidelines-based glucose control. The endpoint for both objectives is progression of two or more steps on the modified ETDRS classification [16]. In addition to the primary objectives, three secondary objectives have been defined. These are, first, to quantify the degree of misclassification of background and proliferative retinopathy and macular oedema diagnosed by fundoscopy, as used in the main ADVANCE study; second, to investigate if blood pressure lowering with an ACE inhibitor diuretic combination prevents the incidence and progression of retinal vascular lesions and distortion of retinal vascular geometry compared to placebo; and third, to investigate if intensive glucose control prevents the incidence and progression of retinal vascular lesions and distortion of retinal vascular geometry compared to standard glucose control. 3. Methods 3.1. Intervention ADVANCE is a 2 factorial, randomised controlled trial in 11140 patients with type 2 diabetes mellitus receiving standard care. The protocol has been published previously [21]. In short, inclusion is not based on glycemic control or blood pressure, but on an elevated risk of vascular disease. This is defined by at least one of a number of risk factors, including longstanding diabetes 10 years ; , older age 65 years ; , history of cardiovascular disease or diabetes complications, and elevated levels of cardiovascular risk factors. The two primary endpoints are composite measures of macro- and microvascular disorders, respectively [21, 22]. Among all ADVANCE participants, retinopathy is routinely assessed by direct fundoscopy and clinical data, such as laser coagulation treatment, are recorded. Following a 6-week run-in phase on active blood pressure lowering treatment and usual glucose lowering treatment, eligible participants were randomly assigned in a 2 factorial design to one of four treatment combinations. The two randomized comparisons are a double-blind comparison of blood pressure lowering versus placebo and an open comparison of intensive glucose lowering therapy targeting an HbA1c of 6.5% or less versus standard guidelines-based glucose lowering. The blood pressure treatment is a fixed low-dose combination of perindopril 24 mg ; and indapamide 0.6251.25 mg ; . For patients in whom an ACE-inhibitor is indicated, background perindopril open label, 2 or 4 mg ; is provided. There is no restriction in prescribing other blood pressure lowering medication if deemed necessary by the treating physician. Intensive glucose control starts with a long-acting sulphonylurea gliclazide MR 30120 mg ; , to which other oral glucose lowering agents and insulin may be added to reach the HbA1c of 6.5% or less, at the discretion of the treating physician. It is important to realize that ADVANCE is a pragmatic study that recognizes variations in standard care. Randomization is stratified by study center, history of macro- or microvascular disease and background use of perindopril at baseline. The scheduled average follow-up is 5.5 years and final results of the main ADVANCE study are anticipated to be available in 2007 [21, 22]. 3.2. Participants AdRem is conducted in patients that have been randomized in the ADVANCE trial in a selected number of study centers with access to retinal cameras. In addition to the inclusion and exclusion criteria of ADVANCE, patients who had a previous ophthalmologic intervention procedure in one or both eyes that might interfere with retinal circulation such as laser coagulation treatment and vitrectomy ; were excluded from AdRem. Patients were also excluded if it was unlikely that good quality stereo photographs could be taken, for example due to the presence of severe cataract or pupils that did not dilate at least 4 mm. At each AdRem study center all ADVANCE patients were eligible for the AdRem sub-study. 3.3. Photography Photographs are taken with 35 mm high quality color films Kodak EPR64 13536 ; . These are provided by the AdRem Substudy Coordination Center, where a large quantity of a single batch is stored at - 20 C until required. Retinal cameras with an angle between 30 and 35 and 2.5 magnification, without special stereo equipment, are used. Stereoscopic photographs are made of both left and right eyes, according to the seven-standard fields ETDRS protocol [23]. The seven fields include one centered on the optic disc, one centered on the macula, one temporal to the macula, two superior and two inferior fields Fig. 1. No generic products are available in this class. Brand is no longer available. PDL Preferred Drug List and rosuvastatin.
Ad hoc basis, with subsequent risks of poor patient motivation, PEP side effects, non-adherence, and abandonment of safe sex practices. Accordingly, post-sexual prophylaxis should not be administered. HIV and Occupational Health In addition to PEP, other health interventions can reduce the frequency of workplace injury and illness: Hepatitis B vaccination is safe and effective, and will reduce the incidence of occupationally acquired hepatitis B, which can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Appropriate respiratory precautions for patients with active TB will reduce the risk of occupationally acquired TB, which is a serious hazard for all HCWs, but especially those who are HIV-infected. Surgery and Medically Invasive Procedures on HIV-Infected Patients As HAART extends patient life-expectacy to that of non-infected persons, the need for surgical or invasive medical procedures on HIV-infected patients will increase. The medical literature on surgical risk for HIV-infected patients is largely retrospective, descriptive, and so inconsistent that many surgical specialities have published numerous reports both favourable and unfavourable with regards to post-operative complications in HIV-infected patients. Few studies used analytical methods to control for the many confounding factors associated with surgical risk in general. An extensive meta-analysis of 114 studies of this subject AIDS, Vol. 12 17 ; , November 1998 ; noted these important deficiencies of prior studies, and concluded that "the ultimate outcome of HIV-infected patients is most likely dependent upon many independent variables and not just the underlying viral infection and disease stage." In particular, there has been no consistent evidence of "poor wound healing" in HIV-infected patients after surgery. Thus, lacking any definitive data to the contrary, surgery for HIV-infected patients must not be delayed or ruled out simply on the basis of HIV infection alone. Rather, evaluation for surgery must take into account the overall clinical condition of the patient, including cardiopulmonary status, coagulation profile, baseline level of physical activity, and other non-HIV-related parameters routinely used to judge surgical fitness for patients not infected with HIV. Delay or postponement of surgery cannot be justified by asserting that the HIV-infected patient has a "terminal illness, " since HAART has increased life expectancy for most patients to a normal life span. Nonetheless, HIV infection can cause a variety of acute and chronic conditions which may contra-indicate surgery. As a rule, unless the surgery is an emergency, the following situations are medically valid reasons to delay surgery, until they have first been rectified, ideally with HAART: Any acute WHO clinical stage 3 condition. Remote or resolved stage 3 conditions are not contra-indications to surgery. Any WHO clinical stage 4 condition or symptom, which is acute and which has not resolved. Stage 4 malignancies which are in remission or are resolving e.g. KS responding to therapy ; , are not contra-indications to surgery. All of the treatment trials in high blood pressure BP ; have shown major reductions in the number of people developing strokes, 1 and this reduction for a given BP appears to be equivalent to the epidemiological risk of that elevation in BP, 2 a remarkable achievement, if true, as the risk of stroke is reversed in a very few years of treatment. However, all these studies have been primary prevention studies and there has, until now, remained some controversy over whether the long-term lowering of BP following a stroke carries similar benefits. It was therefore with great anticipation that the results of the PROGRESS study Perindopril Protection Against Recurrent Stroke Study ; , 3 were presented at the European Society of Hypertension Meeting in Milan in June 2001. The results clearly demonstrated a major benefit in stroke reduction by lowering BP in people with a previous history of stroke or transient ischaemic attack TIA ; . Importantly, this benefit was throughout the range of BP; in other words both normotensive and hypertensive individuals who had suffered a stroke or TIA benefited from BP-lowering. Increasing BP is the most important contributory factor to primary stroke. Epidemiological studies show a continuous and graded relationship between BP and the risk of primary stroke, and there is no evidence of any lower BP threshold, below which further reductions in BP have no effect on stroke risk.2 Treatment trials have now and valsartan. 1. 2. 3. Grimm RH and Pool JL. Alpha-adrenergic blockade and its role in hypertension. Available at medscape . Accessed February 2006. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003; 289: 2560-72. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial ALLHAT ; . JAMA 2000; 283: 1967-75. Kastrup EK, ed. Drug Facts and Comparisons. Facts and Comparisons. St. Louis, MO: 2006. Kasiske BL, Ma JZ, Kalil RS, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122: 133-41. Grimm RH and Pool JL. Alpha-adrenergic blockade and its role in hypertension. Available at medscape . Accessed February 2006. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization WHO ; International Society of Hypertension ISH ; statement on management of hypertension. J Hypertens. 2003; 21: 1983-92. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 BHS-IV ; : summary. BMJ. 2004; 328: 634-40. European Society of Hypertension-European Society of Cardiology. 2003 guidelines for the management of arterial hypertension. J Hypertens. 2003; 21 6 ; : 1011-53. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163: 525-42. American Diabetes Association. Standards of medical care in diabetes: position statement. Diabetes Care. 2005; 28: S4-S36. National Kidney Foundation. K DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic renal disease. J Kidney Dis 2004; 43 5 Suppl 1 ; : S1-290. National Institute for Clinical Excellence. Management of hypertension in adults in primary care. London : National Institute for Clinical Excellence; 2004. Abramowicz M, ed. Treatment guidelines: drugs for hypertension. The Medical Letter. 2005; 3 34 ; : 39-48. American Urological Association. The management of benign prostatic hyperplasia. Baltimore, MD: American Urological Association, Inc.; 2003. Tatro DS, ed. Drug Interaction Facts. Facts and Comparison. St. Louis, MO: 2006. Klasco RK, ed. DRUGDEX System. Thomson Micromedex, Greenwood Village, CO; edition expires 2006. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus [alpha]-blocker as first-step antihypertensive therapy: final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial ALLHAT ; . JAMA 2003; 42 3 ; : 239-46. Barzilay JI, Davis BR, Bettencourt J, et al. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens 2004; 6 3 ; : 116-25. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. Final results. JAMA 1993; 270 6 ; : 713-24. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritionalhygienic therapy in the treatment of mild hypertension study TOMHS ; . Circulation 1995; 91: 698706. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood.
Those of the 4 previous trials combined 2742 ; . The active treatment consisted of 1 or drugs: always the angiotensinconverting enzyme ACE ; inhibitor perindopril 4 mg per day ; , in 58% of cases also the diuretic agent indapamide mostly 2.5 mg per day ; . The choice between combined treatment or double placebo ; and perindopril alone or single placebo ; was left to the discretion of the physician. Importantly, existing antihypertensive treatment was continued in an unchanged fashion 50% of patients in the 2-drug group, 51% in the perindopril-only group the same applied to other drugs such as antiplatelet agents. After an average follow-up period of almost 4 years in the PROGRESS trial, the rate of major vascular events vascular death, nonfatal stroke, or vascular death ; was 5.5% per annum in the placebo group. This hazard was reduced to an annual rate of 4.1%, ie, by 26% 95% CI 16% to 34% ; in all patients on active drug treatment combined or single ; . This result was driven mainly by the patients on combined treatment 40% reduction of major vascular events, 95% CI 29% to 49% ; , in whom blood pressure was lowered by a mean of 12 5 Hg. There was a nonsignificant hazard reduction of 4% 95% CI 15% to 20% ; by perindopril alone, associated with a mean blood pressure reduction of 5 3 Hg. The difference between the effects of combined and single drug treatment remained the same after correction for baseline imbalances. Patients with a baseline blood pressure above 160 90 mm Hg benefited somewhat more 29% reduction of major vascular events, 95% CI 16% to 40% ; than nonhypertensive participants 24%, 95% CI 9% to 37% this difference was attributable almost exclusively to the perindopril-only group. Strokes were prevented to the same degree as other vascular events, and equally in different stroke types: fatal or disabling versus moderately disabling, and ischemic versus hemorrhagic stroke. The internal validity of the PROGRESS study seems unquestionable. The choice of outcome events is realistic in that they reflect the patient's point of view that it is important not only to avoid strokes, but also to avoid sudden death or myocardial infarction. A plea to restrict analysis to vascular events in the brain can still be heard, 8 but fortunately this "iatrocentric" perspective is on the decline. The results of the PROGRESS study are robust and important. Nevertheless, as so often happens in science, every answer raises new questions. Can the beneficial effects be generalized to everyday neurological practice? Is it only the blood pressure reduction that counts, independent of the drugs used? And should we now really start lowering blood pressure in "normotensive" patients with cerebral ischemia, even in the elderly? The first question in the assessment of the external validity of trial results should always be: "Do I recognize my patients?" 319 and terazosin. Hapatic Faikure Rarely, ACE inhibitors have been assw~d with a syndrome that starta with cholestatic jaundice and progresses to fulminant hepatic necrosis and sometimes ; death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibnora wha develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up. PRECAUTIONS Genarak Impaired Renal Function: As a consequence of inhibiting the renin-engiotensin-aldoaterone syat~m, changes in renal function may be anticipated in susceptible individuals. Hypertensive Patients with Corrgestive Heart Failure: In patients with severe congestive heart failure, where renal function may depend on the activity of the renin-angiotensin-aldoaterone system, treatment with ACE inhibitors, including ACEON, may be aasociatad with oliguria and or progressive azotemia, and rarely with acute ranal failure and or death. Hypertensive Patienta with Renal Artery Stanosis: in hypertensive patients with unilateral or biiateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine may occur. Experience with ACE inhibitors suggests that these increases are usually reversible upon discon~inuation of the drug. In such patients, renal function should be~monitored during the first few weeka of therapy. Some hypertensive patients without apparent pra-exieting renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient. These increases are more likely to occur in patienta treated concomitantly with a diuretic and in patients with pre-existing renal impairment. Reduction of dosages of ACEON, the diuretic or both may be required. In some cases, discontinuation of either or both drugs may be necessary. Evaluation of hypertensive patients should always include an assessment of renal function. ace DOSAGE AND ADMINISTR& TUkN Hyperka errria: Elevationa of serum potassium have been observed in some patients treatad with ACE inhibfiors, inciudhg ACEON. In U.S. controlled clinical trials, 1.4% of the patients receiving ACEON and 2.3% of patients rweiving placebo showed increased serum potassium levels to greater than 5.7 mE . Most cases were isolated single values that did not appear clinically relevant and were rarely a cause for withdrawal. Risk factors for the development of hyperkelemia include renal insufficiency, diabetes mellitua and the concomitant use of agents such as potaaa-mmsparing diuretics, potassium supplements and or potaesium * ontaining salt substitutes. Drugs associated with increases in serum potassium should be used cautiously. if at all, with ACEON. see PRECAUTIONS: Drug Interactions. ; Cough: Presumably due to the inhibition of the degradation of endogenoua bradykinin, persistent nonproductive cough has bean reported vAth all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the dblerential diagnosis of cough. In controlled trials with perindopril, cough was present in 12% of perindopril patients and 4.6% of patients given placebo. Surgery Anestlresisr In patienta undergoing surgery or during anesthesia with agenta that produce hypotension, ACEON may block angiotensin II formation that would otfrerwiae occur secondaty to compensatory renin release. Hypotension attributable to this mechanism can be corrected by volume expansion. Information for Patients Angioederna: Angioedema, including laryngeal edema, can occur with ACE inhibitor therapy, especially following the first dose. Patients should be told to report immediately signs or symptoms suggesting angioedema swelling of face, extremities, eyes, lips, tongue, hoarseness or difficulty in swallowing or breathing ; and to take no more drug before consulting a physician. Syrrrptomatjc Hypotension: As with any antihypertensive therapy, patients should be cautioned that lightheadedness can occur, especially during the first few days of therapy and that it should be reported promptly. Patients should be told that if fainting occurs, ACEON should be discontinued and a physician consulted. All patie, nts should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea or vomiting can lead to an excessive fall in blood pressure in association with ACE inhibitor therapy. Hyperkdernia; Patients shouid be advised not to use potassium supplements or salt substitutes containing potassium without a physician's advice. Neurroperria: Patients should be told to report promptly any indication of infection e.g., sore throat, fever ; which could be a sign of neutropenia. Pregnancy: Female patients of childbearing age should be told about the consequences of second and third trimester exposure. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial the europa study and candesartan and Order perindopril.